The two largest private companies in the growing spatial biology segment, Vizgen and Ultivue, said they have merged into a single entity that will offer both single-cell spatial genomics and multiplex proteomic profiling technologies to customers engaged in foundational and clinical research. The combined company—which will carry the Vizgen name—will build upon its namesake predecessor’s expertise in single-cell spatial genomics and Ultivue’s leadership in multiplex proteomic profiling. The new Vizgen also aims to increase its presence in clinical lab settings while continuing to serve customers in research institutions and biopharmas.
“I firmly believe that for spatial analysis to reach its full potential, it’s going to have to reach into the point of having clinical utility,” Rob Carson, president and CEO of the newly combined Vizgen, told . “In order to do that, you not only have to have very robust techniques and efficient workflows, you have to have a level of sensitivity that allows a clinician to take very high confidence action.” “The level of information provided by high-fidelity spatial analysis is clearly proving its value.
It’s that continued course down the reproducibility trajectory and evidence generation that’s going to allow for one day the leap into the clinic,” Carson explained. “I think we’re seeing that movement, that inevitable trajectory not only toward reproducibility and robustness, but also toward very high-performance r.